Heterologous Antibody

2016 ◽  
Author(s):  
Douglas M. Templeton ◽  
Michael Schwenk ◽  
Reinhild Klein ◽  
John H. Duffus
Keyword(s):  
Heterologous Antibody

scholarly journals A non-specific complement-fixing system in foot-and-mouth disease and experiments on the absorption of heterologous antibody from serum

1956 ◽  
Vol 54 (3) ◽  
pp. 328-334 ◽  
Author(s):  
J. B. Brooksby ◽  
S. Erichsen
Keyword(s):  
Complement Fixation ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Foot And Mouth ◽  
Heterologous Antibody

Stored mixtures of the virus and corresponding antisera in foot-and-mouth disease have equal complement-fixing activity whether they are prepared from virus and serum of homologous or heterologous types. On ultracentrifugation the complement-fixing activity is removed from the mixture and the remaining antibody is more sharply type-specific in routine complement-fixation tests than the original serum.

scholarly journals Homologous and Heterologous Antibody Responses of Mice Immunized with Purified Feline Herpesvirus Type 1 and Canine Herpesvirus Glycoproteins.

1991 ◽  
Vol 53 (3) ◽  
pp. 423-432 ◽  
Author(s):  
Joselito A. LIMCUMPAO ◽  
Taisuke HORIMOTO ◽  
Xuenan XUAN ◽  
Yukinobu TOHYA ◽  
Masayuki AZETAKA ◽  
...  
Keyword(s):  
Antibody Responses ◽  
Herpesvirus Type ◽  
Canine Herpesvirus ◽  
Feline Herpesvirus ◽  
Feline Herpesvirus Type 1 ◽  
Heterologous Antibody

Neutralization of Interferon Activity in Homologous and Heterologous Cells with Homologous and Heterologous Antibody

1980 ◽  
Vol 165 (1) ◽  
pp. 161-166 ◽  
Author(s):  
I. A. Braude ◽  
E. De Clercq ◽  
Z. Zhen-Xi ◽  
V. G. Edy ◽  
P. DeSomer
Keyword(s):  
Interferon Activity ◽  
Heterologous Antibody

scholarly journals Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects

2012 ◽  
Vol 19 (12) ◽  
pp. 1943-1948 ◽  
Author(s):  
Iván Bihari ◽  
Gyula Pánczél ◽  
Jozsef Kovacs ◽  
Jenny Beygo ◽  
Elena Fragapane
Keyword(s):  
Influenza Vaccine ◽  
Vaccine Strain ◽  
Influenza Pandemic ◽  
Vaccine Dose ◽  
The Elderly ◽  
Antibody Responses ◽  
Elderly Subjects ◽  
H5n1 Influenza ◽  
Reactive Antibody ◽  
Heterologous Antibody

ABSTRACTPreparedness against an A/H5N1 influenza pandemic requires well-tolerated, effective vaccines which provide both vaccine strain-specific and heterologous, cross-clade protection. This study was conducted to assess the immunogenicity and safety profile of an MF59-adjuvanted, prepandemic influenza vaccine containing A/turkey/Turkey/01/2005 (H5N1) strain viral antigen. A total of 343 participants, 194 adults (18 to 60 years) and 149 elderly individuals (≥61 years), received two doses of the investigational vaccine given 3 weeks apart. Homologous and heterologous antibody responses were analyzed by hemagglutination inhibition (HI), single radial hemolysis (SRH), and microneutralization (MN) assays 3 weeks after administration of the first vaccine dose and 3 weeks and 6 months after the second dose. Immunogenicity was assessed according to European licensure criteria for pandemic influenza vaccines. After two vaccine doses, all three European licensure criteria were met for adult and elderly subjects against the homologous vaccine strain, A/turkey/Turkey/1/2005, when analyzed by HI and SRH assays. Cross-reactive antibody responses were observed by HI and SRH analyses against the heterologous H5N1 strains, A/Indonesia/5/2005 and A/Vietnam/1194/2004, in adult and elderly subjects. Solicited local and systemic reactions were mostly mild to moderate in severity and occurred less frequently in the elderly than in adult vaccinees. In both adult and elderly subjects, MF59-adjuvanted vaccine containing 7.5 μg of A/Turkey strain influenza virus antigen was highly immunogenic, well tolerated, and able to elicit cross-clade, heterologous antibody responses against A/Indonesia and A/Vietnam strains 6 weeks after the first vaccination.

Suppression of tumor growth by a heterologous antibody directed against multiple myeloma dominant CD38 antigen in SCID mice injected with multiple myeloma cells

2017 ◽  
Vol 24 (3-4) ◽  
pp. 53-57 ◽  
Author(s):  
Arpad Z. Barabas ◽  
Chad D. Cole ◽  
Richard M. Graeff ◽  
Zoltan B. Kovacs ◽  
Rene Lafreniere
Keyword(s):  
Multiple Myeloma ◽  
Tumor Growth ◽  
Scid Mice ◽  
Myeloma Cells ◽  
Cd38 Antigen ◽  
Heterologous Antibody
Sign in / Sign up

Export Citation Format

Share Document